ICU中的体温管理
本文为综合性综述,检索MEDLINE并评价心脏骤停、急性缺血性及出血性卒中、创伤性脑损伤和脓毒症中体温管理(包括目标温度管理和退热治疗)的证据。最有力的治疗性低温证据见于心脏骤停后昏迷幸存者,近期试验提示骤停后目标温度33°C至37.5°C合理。其他重症的目标温度管理在大规模临床试验中未显示获益;药物退热试验亦未改善结局,但国家指南基于观察性证据推荐对卒中及创伤性脑损伤患者发热进行处理。
要点
- 心脏骤停后昏迷幸存者:近期试验提示骤停后目标温度33°C至37.5°C合理。
- 急性卒中、创伤性脑损伤和脓毒症的目标温度管理在大规模临床试验中未显示获益。
- 药物退热治疗试验未显示改善结局。
- 国家指南基于观察性证据(发热与更差结局相关)推荐对卒中及创伤性脑损伤患者发热进行处理。
- 重症患者体温管理仍需进一步研究以明确管理策略和治疗路径。
适用人群与场景
- 危重症患者,包括心脏骤停后昏迷幸存者、急性缺血性和出血性卒中、创伤性脑损伤及脓毒症患者。
处置流程与药物剂量
- 心脏骤停后昏迷幸存者:骤停后目标温度33°C至37.5°C合理。
- 卒中及创伤性脑损伤患者:国家指南推荐对发热进行处理(基于观察性证据)。
研究设计与关键结果
- 综述类型:综合性综述,检索MEDLINE并追溯纳入文献的参考文献,纳入英文系统评价、Meta分析、随机试验、观察性研究及非人类数据,重点关注最新随机对照试验证据,数据定性评估。
- 心脏骤停后昏迷幸存者:治疗性低温证据最强,近期试验提示骤停后目标温度33°C至37.5°C合理。
- 急性卒中、创伤性脑损伤和脓毒症:目标温度管理在大规模临床试验中未显示获益。
- 药物退热治疗:试验未显示改善结局;但国家指南基于观察性证据(发热与更差结局相关)推荐对卒中及创伤性脑损伤患者发热进行处理。
证据类型、等级与局限
- 证据类型:综合性综述,纳入系统评价、Meta分析、随机试验、观察性研究及非人类数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 心脏骤停后昏迷幸存者可将骤停后目标温度控制在33°C至37.5°C。
- 对卒中及创伤性脑损伤患者发热进行处理,依据为国家指南基于观察性证据的推荐。
- 急性卒中、创伤性脑损伤和脓毒症的目标温度管理在大规模临床试验中未显示获益。
- 药物退热治疗未显示改善结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Temperature abnormalities are recognized as a marker of human disease, and the therapeutic value of temperature is an attractive treatment target. The objective of this synthetic review is to summarize and critically appraise evidence for active temperature management in critically ill patients.
DATA SOURCES: We searched MEDLINE for publications relevant to body temperature management (including targeted temperature management and antipyretic therapy) in cardiac arrest, acute ischemic and hemorrhagic stroke, traumatic brain injury, and sepsis. Bibliographies of included articles were also searched to identify additional relevant studies.
STUDY SELECTION: English-language systematic reviews, meta-analyses, randomized trials, observational studies, and nonhuman data were reviewed, with a focus on the most recent randomized control trial evidence.
DATA EXTRACTION: Data regarding study methodology, patient population, temperature management strategy, and clinical outcomes were qualitatively assessed.
DATA SYNTHESIS: Temperature management is common in critically ill patients, and multiple large trials have been conducted to elucidate temperature targets, management strategies, and timing. The strongest data concerning the use of therapeutic hypothermia exist in comatose survivors of cardiac arrest, and recent trials suggest that appropriate postarrest temperature targets between 33°C and 37.5°C are reasonable. Targeted temperature management in other critical illnesses, including acute stroke, traumatic brain injury, and sepsis, has not shown benefit in large clinical trials. Likewise, trials of pharmacologic antipyretic therapy have not demonstrated improved outcomes, although national guidelines do recommend treatment of fever in patients with stroke and traumatic brain injury based on observational evidence associating fever with worse outcomes.
CONCLUSIONS: Body temperature management in critically ill patients remains an appealing therapy for several illnesses, and additional studies are needed to clarify management strategies and therapeutic pathways.
参考来源
- Drewry A, Mohr NM. Temperature Management in the ICU. Crit Care Med. 2022. PMID: 35426840. doi:10.1097/CCM.0000000000005556
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。